Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070275 | 1.00 | LGALS9 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL12392953 | 1.00 | LGALS9 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL15215757 | 1.00 | LGALS9 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| Hydrochloric Acid SCHEMBL782523 | 0.99 | LGALS9 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL802389 | 0.87 | LGALS9 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL15095818 | 0.82 | LGALS9 (0.44) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL18896495 | 0.79 | LGALS9 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL18900577 | 0.77 | CHRNA7 (0.41) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL12392959 | 0.77 | SMN1; SMN2 (0.43) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 | |
| SCHEMBL12069028 | 0.75 | LGALS9 (0.45) | LGALS9LGALS1LGALS3LGALS7; LGALS7BCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216960-B2 | Spiro[2.4]heptanes for treatment of Flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8946242-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8921384-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140140958-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140957-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673926-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130224152-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140958-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | LGALS9 2528/4885LGALS1 1871/4885LGALS3 2282/4885 |
| US-20130224152-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | LGALS9 2528/4885LGALS1 1871/4885LGALS3 2282/4885 |
| US-20140140957-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | LGALS9 2528/4885LGALS1 1871/4885LGALS3 2282/4885 |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | LGALS9 2528/4885LGALS1 1871/4885LGALS3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.